It's time for new treatments in pancreatic cancer pathology

Ramona Crişan, Mihaela Aldea, Gabriel Kacso

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

Résumé

Background and aims: The objective of this study was to conclude if there are enough scientific evidences to consider metformin as a potential treatment for pancreatic cancer. Material and Method: We performed a systematic search using PubMed and MedlinePlus up to September 2012. Reference list of relevant peer-reviewed literature were hand searched. Ultimately 15 articles were included. Results: Epidemiological studies had revealed that therapy with metformin was associated with 21% reduced risk for all types of malignancies, 31% reduction in overall summary relative risk, the median survival was longer: 16.6 vs. 11.5 months and the risk of death has decreased with 33%. In vitro it was proven that low doses of metformin block the stimulation of DNA synthesis and the growth of human pancreatic cancer cells. Prospective randomized clinical trials to confirm these data were already launched. Conclusions: These results raise the possibility that metformin could improve the poor prognostic of patients suffering from pancreatic cancer. Other clinical trials should confirm this hypothesis.

langue originaleAnglais
Pages (de - à)69-75
Nombre de pages7
journalRomanian Journal of Diabetes, Nutrition and Metabolic Diseases
Volume20
Numéro de publication1
Les DOIs
étatPublié - 1 janv. 2013
Modification externeOui

Contient cette citation